Precision BioSciences Inc (DTIL) released its first quarter results on Thursday, May 13, 2021. The company reported net earnings of $-0.33 per share for the first quarter ending March 31, 2021. Earnings for this past quarter were up 37 percent compared to the same period a year ago.
Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food.
Precision BioSciences' revenue increased 41 percent over the past trailing twelve-month period versus the previous twelve-month period. Operating margins increased to 114.64% over the same period. Net earnings for past trailing twelve months were $-100.86 million, down 15% from the prior year.
Moving on to the balance sheet, Precision BioSciences' cash levels jumped 25% for the first quarter over the same period last year. Overall liquidity of the balance sheet, as measured by the current ratio, decreased 51.09% this past year. The current ratio for Precision BioSciences now stands at 3.43. The company increased shares outstanding by 11.23%.
Shares of DTIL are currently trading around $9.50. In terms of valuation, the stock is trading at a price to book ratio of 9.15.
_____
This article was written by Value Investing News (https://www.valueinvestingnews.com) on Saturday, May 15, 2021.